Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

OMZ reported for 6 months of 2023 by RAS

7/31/23 OMZZP

The Chevron announced a quarterly dividend

7/31/23 CVX

YTEK reported for 6 months of 2023 by RAS

7/31/23 YAKG

MD Medical's revenue in the first half of the year increased by 5.7%

7/31/23 MDMG

Moscow Exchange switched to a unified trading and settlement mode T+1

7/31/23 MOEX

TNS Energo Voronezh reported for 6 months of 2023 by RAS

7/31/23 VRSB

MS-21 airliner project will receive about ₽280 billion from National Welfare Fund

7/31/23 IRKT

Pyaterochka restored its license to sell alcohol in St. Petersburg

7/31/23 -

The Exxon Mobil announced a quarterly dividend

7/31/23 XOM

Biogen acquires Reata Pharmaceuticals

7/28/23 RETA